Tinnitus Treatments Inspired by Neurodegenerative Research

Tinnitus is a symptom of maladaptive neuroplasticity, sharing core biological mechanisms with neurodegenerative diseases like Alzheimer’s and Parkinson’s. This mechanistic overlap, detailed in a new review by J L Liu and Peng Liu, suggests established neuroprotective treatments could be repurposed to treat persistent tinnitus.

How Neurodegeneration Research Informs Tinnitus Models

The review, published in Frontiers in Aging Neuroscience, systematically compares the pathophysiology of chronic tinnitus and neurodegenerative disorders. The authors identified three primary overlapping pathways: neuroinflammation, glutamate-mediated excitotoxicity, and dysregulation of neurotrophic support.

In both conditions, prolonged inflammatory responses in the brain can damage neurons and synapses. Excessive glutamate, the brain’s main excitatory chemical, can overstimulate and kill auditory neurons, a process known as excitotoxicity. Furthermore, a deficit in neurotrophic factors like BDNF, which are essential for neuronal survival and plasticity, is common. This breakdown in cellular maintenance and communication leads to the maladaptive rewiring of neural networks responsible for generating the tinnitus percept. The paper argues that because these core mechanisms are shared, therapies designed to interrupt them in one condition may be effective for the other.

Potential Drug Candidates from the Neurodegeneration Pipeline

Liu and Liu examined several classes of compounds with established research in neurodegeneration for their potential application in tinnitus.

Targeting Neuroinflammation

Drugs that suppress chronic brain inflammation are a primary focus. Anti-inflammatory agents, including specific cytokine inhibitors and modulators of microglial activation, have reduced tinnitus-like behavior in animal studies. By calming this inflammatory state, these treatments may prevent further damage to auditory pathways and allow healthier neural function to resume.

Calming Glutamate Excitotoxicity

Memantine, an NMDA receptor antagonist used in Alzheimer’s disease, has been investigated for tinnitus. It works by blocking the receptors responsible for glutamate’s excitotoxic effects. While some clinical trials have shown mixed results, the review notes that preclinical data strongly supports the mechanism. Refinements in dosing, timing, and patient selection could improve outcomes, an approach supported by a separate analysis of sudden hearing loss treatments where timing is critical.

Boosting Neurotrophic Support

A particularly promising strategy involves enhancing levels of brain-derived neurotrophic factor (BDNF). Low BDNF is linked to both neurodegeneration and tinnitus severity. Drugs or other interventions that increase BDNF could promote the survival and proper function of auditory neurons. This approach aligns with broader neuromodulation strategies, such as those discussed in our review of neuromodulation for tinnitus, which often seek to restore balanced brain activity.

Current Evidence and the Path to Clinical Use

The evidence supporting this drug repurposing strategy is currently stronger in the lab than in the clinic. Numerous preclinical studies in rodent models of tinnitus show that these neuroprotective drugs can reduce behavioral signs of tinnitus and reverse associated neural changes.

Translational and early-stage clinical research, however, is less robust. The authors point to a need for more targeted human trials that select patients based on biomarkers aligned with these specific mechanisms, rather than treating tinnitus as a single condition. This precision medicine approach could identify which patients are most likely to benefit from an anti-inflammatory versus an anti-excitotoxicity drug. The complex nature of tinnitus often involves tinnitus and anxiety, suggesting future trials may also need to account for these overlapping networks.

Practical Implications for Tinnitus Treatment Development

This research framework has two major practical implications. First, it provides a strong rationale for launching new clinical trials testing existing, safe neuroprotective drugs for tinnitus. Repurposing drugs with known safety profiles can significantly shorten the development timeline compared to creating new molecules.

Second, it shifts the focus toward mechanism-based treatment. If clinicians can identify the dominant pathological pathway in an individual—be it inflammation or excitotoxicity—they could prescribe a more targeted therapy. This represents a move away from a one-size-fits-all model and toward personalized audiological medicine.

The review by Liu and Liu establishes a clear scientific bridge between auditory and neurodegenerative research. By borrowing therapeutic strategies from the fight against Alzheimer’s and Parkinson’s, researchers may find effective new tools to quiet the persistent sound of tinnitus.

Source: Liu JL, Liu P. (2026). Tinnitus as a neurodegenerative disease: therapeutic implications for drug repurposing. Front Aging Neurosci. doi: 10.3389/fnagi.2026.1835649.